Alcyone Lifesciences appoints Michael Rogawski to Clinical and Scientific Advisory Board


Alcyone Lifesciences has announced the appointment of Michael Rogawski of the University of California, Davis, USA to its clinical and scientific advisory board.

“Throughout his career, Rogawski has been in the forefront of bringing novel and effective treatment for hard to treat seizures and epilepsy,” says PJ Anand, founder and chief executive officer, Alcyone Lifesciences. “His research continues to drive significant advancement in the field and we look forward to his contribution to Alcyone.”

“Alcyone’s technology platform is unique in that it has the potential to significantly improve certain seizure and epileptic conditions and offer new possibilities to help patients with this debilitating condition. I am looking forward to working with the talented Alcyone team,” says Rogawski.

Rogawski is an internationally recognised expert on treatments for seizures and epilepsy. He is currently professor of neurology and member of the Center for Neuroscience at the University of California, Davis. Until 2006, he was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. Rogawski’s research encompasses cellular neurophysiological studies of ion channels and animal seizure models. He was the first to investigate convection-enhanced delivery of anti-seizure agents in the treatment of epilepsy. In recognition of his research contributions, Rogawski received the NIH Director’s Award and the Epilepsy Research Award from the American Society for Pharmacology and Experimental Therapeutics. He presented the William G Lennox Lecture of the American Epilepsy Society.

Rogawski received his bachelor’s degree in biophysics from Amherst College, and MD and PhD in pharmacology from Yale. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology at NINDS, he completed residency training in neurology at Johns Hopkins.